Is nSTRIDE APS Safe for Knee Osteoarthritis? Clinical Evidence and Risks in Singapore

If you’re searching “APS injection safety Singapore,” you’re likely comparing options for knee osteoarthritis (OA) especially if knee pain is affecting daily life, such as climbing stairs, commuting, exercising, or standing for long periods at work.

With any intra-articular injection, it’s normal to focus on safety first. Patients commonly want to know what side effects to expect, how often complications occur, whether the treatment performs similarly to saline (placebo) in clinical trials, whether an autologous approach (using your own blood) changes the risk profile and what symptoms after an injection should prompt medical review.

If you’re reviewing your options, you can start by reading our guide on knee joint injection options in Singapore and our overview of knee pain and stiffness treatment in Singapore.

This article summarises what published clinical studies report about nSTRIDE® Autologous Protein Solution (APS) and places that information in context with general knee injection side effects.

What is nSTRIDE APS?

nSTRIDE APS refers to an Autologous Protein Solution (APS) prepared from a small sample of the patient’s own blood using a point-of-care device system. The output is typically around 2–3 cc which is injected into the knee joint (intra-articular injection).

The manufacturer describes APS as a concentrated solution containing white blood cells, platelets and plasma proteins in a small volume of plasma.

Why APS is discussed for knee OA

Knee osteoarthritis (OA) is associated with increased inflammatory signalling within the joint environment. APS is designed to concentrate anti-inflammatory mediators—such as IL-1 receptor antagonist and soluble TNF receptors—alongside selected growth factors, with the aim of shifting the intra-articular balance away from inflammation.

In the context of knee OA management, APS is often discussed alongside other intra-articular options. In Singapore, commonly considered alternatives include hyaluronic acid knee injections and Conjuran (PN) knee injections, depending on OA severity, symptom pattern, and patient goals.

A 2019 review of intra-articular treatments for knee OA describes APS conceptually as an autologous “cell concentrate” produced from a patient’s blood, reflecting its positioning within the broader category of orthobiologic injectables.

Summary of key clinical evidence on nSTRIDE APS safety

1) Open-label safety study (2016): no serious adverse events reported

A 2016 open-label study (small sample) reported that patients were monitored for adverse events following a single APS injection. The published report notes no serious adverse events and no events rated greater than mild, with minor issues such as injection-site discomfort/joint pain and nausea that resolved without treatment.

What this tells you (and what it doesn’t):

• It supports basic short-term tolerability in a small group.

• Because it’s small and open-label, it cannot detect rare complications well and is not designed to compare rates against saline.

2) Pilot double-blind RCT (PROGRESS II): comparable safety to saline

A multicentre pilot randomised controlled trial is commonly cited for APS. Zimmer Biomet’s summary of the trial reported no procedure- or device-related serious adverse events and that the frequency/severity/relatedness of adverse events were comparable to saline.

The PubMed record for this trial (Kon et al.) concludes the study supports safety at 1-year follow-up.

What this tells you:

• In a controlled setting, APS did not show a higher serious adverse event signal than saline (based on the trial’s size).

3) Additional pilot/open-label publication: minor AEs were common but resolved

A separate open-label pilot report (10 treated patients) notes that minor adverse events were experienced by a majority of participants, but the paper reports no unanticipated adverse events attributable to the device and describes resolution without further intervention.

How to interpret this:

• “Minor” AEs can still matter to patients (temporary swelling, discomfort, stiffness), even if they are not medically serious.

• It suggests a pattern consistent with “procedure-related” symptoms rather than device-specific harm.

4) 3-year follow-up publication: reported as safe in mild–moderate OA

A longer-term follow-up (Kon et al., 2020) reports intra-articular APS use in mild to moderate knee OA as safe, with outcomes tracked over multiple years.

What this tells you:

• There is published longer-term follow-up, though it still reflects specific trial settings and patient selection.

5) 2024 trial result worth knowing: no AEs recorded, but pain outcomes favoured saline at 12 months

A 2024 study reported no adverse events recorded in either APS or saline groups, but also reported no meaningful differences in WOMAC/KOOS over time and found pain scores favoured saline at 12 months on certain measures.

Why include this in a “safety” article?

• It highlights that newer data may show different effectiveness outcomes even when safety signals remain low in the study.

6) Reviews: “acceptable safety,” evidence still evolving

A 2024 scoping review concluded intra-articular APS administration is generally safe and may mitigate symptoms, while also reflecting that evidence quality and study designs vary.

What side effects are expected with nSTRIDE APS?

The manufacturer’s information lists side effects that may occur related to the blood draw and/or knee injection, including bruising, local pain, or swelling.

In published studies, commonly reported issues tend to fall into the same broad bucket: temporary discomfort, swelling, stiffness, or soreness, typically resolving without specific treatment.

Common side effects (generally mild and temporary)

These are commonly discussed across intra-articular injections and are consistent with what APS studies report:

• Localised knee soreness after injection

• Transient swelling or stiffness

• Bruising from blood draw

• Temporary discomfort at injection site

Less common use for most joint injections)

Even if not prominent in small trials, clinicians still screen and counsel for general injection-related risks:

• Infection (rare, but clinically serious)

• Bleeding/bruising risk (higher if on certain blood thinners)

• Short-term flare reaction (increased pain/swelling temporarily)

• Vasovagal symptoms (lightheadedness/nausea) during procedures (reported in at least one small APS safety study)

If you develop significant worsening pain, fever, increasing redness/warmth, or feel unwell after an injection, you should seek urgent medical evaluation.

Does “autologous” mean fewer safety issues?

“Autologous” means the injected material comes from your own blood.

That can reduce the likelihood of allergic reactions to foreign substances, because no external drug molecule (like a steroid) is being introduced. However:

• It does not remove general injection risks (infection, bleeding, post-injection flare).

• It does not guarantee you will have no side effects and temporary swelling/discomfort can still occur.

Who may be considered for APS in Singapore?

Typical patient profile in studies and Singapore hospital discussion

APS is usually discussed for mild to moderate knee OA, often graded as Kellgren–Lawrence (KL) grade 1–3 in practice settings.

A SingHealth educational article describes APS (nSTRIDE) as an orthobiologic option used for knee OA in their context, noting it targets inflammatory pathways (IL‑1β and TNFα) and describes a single injection approach.

Why this matters: Most injection options tend to perform differently depending on OA severity. Later-stage OA (e.g., KL4) may respond less reliably and surge relevant discussion for function and pain.

Who might not be suitable?

Your clinician will screen for contraindications and risk factors. Even without listing every contraindication (which can vary by local protocols and product IFU), clinics commonly review:

• Active infection (skin or systemic)

• Bleeding risk or anticoagulation status

• Uncontrolled medical conditions that increase procedural risk

• Whether pain is truly from OA (vs meniscus tear, ligament injury, or referred pain)

• Degree and pattern of OA (e.g., severe deformity or end-stage disease)

What happens on the day of an APS injection?

While exact protocols vary by clinic, the manufacturer describes APS as a point-of-care process involving three main steps: a small blood draw, on-site processing using a separation and concentration system to produce the APS solution, and a single intra-articular injection of approximately 2–3 cc into the knee joint.

Aftercare and downtime: what studies and brochures commonly recommend

It is generally recommended to minimise activity for around 14 days after the injection and not to exceed your pre-injection activity level during this period. Pain relief is often expected to begin within 1–2 weeks and clinical results suggest that benefits may last at least 12 months, although individual responses vary.

In practical terms, many patients in Singapore want to know whether they can walk normally, return to work the next day and resume exercise. The exact advice depends on your clinician’s protocol and your baseline condition, but many programmes follow a similar approach: a short period of reduced loading immediately after the injection, followed by a structured rehabilitation plan to progressively restore strength, function and activity safely.

How does APS safety compare with other common knee injections?

All knee injections share a baseline set of risks because they involve a needle entering the joint. The most common issues across categories are temporary soreness, swelling and stiffness, while infection remains a rare but clinically important complication regardless of the substance injected. The exact likelihood and intensity of side effects vary based on the product used, the injection technique (including whether ultrasound guidance is used), the patient’s medical background and the condition being treated.

Below is a practical comparison of commonly used knee injections and their typical side-effect profiles.

---

Regulatory note to understand

Medical devices supplied in Singapore generally require registration before supply, per HSA guidance.

If you’re researching APS, it’s reasonable to ask your provider:

• what system is used,

• whether it is supplied through appropriate channels and

• what governance and consent process is followed.

 

“Will it cure my knee osteoarthritis?”

OA is generally described as a chronic degenerative condition; current mainstream clinical understanding is that there is no cure for OA, but treatments aim to reduce pain and improve function.

There is no cure for OA, though treatment may reduce or relieve pain. This is an important expectation-setting point: even when a treatment is safe, it may not reverse the underlying structural changes that have accumulated over time.

What a “safety-first” APS consultation should include (Singapore context)

If your priority is APS injection safety, look for a consult that covers:

1. Confirming the diagnosis
   Knee OA pain can overlap with meniscus pathology, tendon pain, referred pain from hip/back, or inflammatory arthritis. APS trials generally focus on OA; misdiagnosis increases the risk of “safe but ineffective” treatment.

2. Severity grading and realistic outcomes
   OA severity influences response rates in several orthobiologic studies.

3. Medication and bleeding risk review
   Because there is blood draw + injection, anticoagulants and bleeding disorders matter.

4. Procedure planning and ultrasound guidance
   Many clinicians use ultrasound guidance to improve injection accuracy by confirming the needle position within the joint in real time. Ultrasound can also help document the joint environment before treatment such as the presence of fluid, synovial thickening, or other findings that may influence procedure planning and aftercare.

5. Aftercare plan
   Activity modification, then a structured return-to-loading plan. The manufacturer suggests minimising activity for 14 days.

FAQ: APS injection safety Singapore

1) Is nSTRIDE APS considered safe in clinical studies?

Across multiple publications, APS has generally been reported as well-tolerated with no device-related serious adverse events reported in early trials and adverse events typically mild and procedure-related.

2) What are the most common knee injection side effects with APS?

Commonly discussed side effects include bruising (from blood draw), local pain and swelling around the knee after injection.

3) How quickly do side effects resolve?

Studies describing adverse events frequently note they resolve without significant intervention, but duration varies by individual and activity level.

4) Is there downtime after APS injection?

Manufacturer guidance recommends minimising activity for about 14 days (not exceeding pre-injection levels).

If you’re considering APS or any knee injection, the priority is not selecting a product first. The priority is confirming the diagnosis, the stage of osteoarthritis, and the likely source of your pain. Two people can both be told they have “knee OA,” yet one person’s symptoms may be driven mainly by inflammation, while another’s may be dominated by mechanical wear, meniscus-related pain, or tendon overload. The plan should match the pain generator, not just the label.

At The Clifford Clinic, we begin with a structured assessment and, when appropriate, an ultrasound evaluation to localise the source of pain and guide decision-making. We then discuss options that fit your findings, which may include rehabilitation and load management, as well as injection-based treatments such as APS. You can read more about our approach to knee joint injection options in Singapore and knee pain and stiffness treatment in Singapore.

If you want to find out whether APS is suitable for your knee and what a safety-first, evidence-aligned pathway looks like for your situation, book a consultation at The Clifford Clinic.